Vol 13, No 3 (2016)

The paper is focused on structure and functions of airway epithelial barrier and allergen-mediated innate immune response of the epithelium leading to facilitation of allergy development.

Conclusion paragraphs were discussed at the Advisory Board and adopted by majority of votes during voting. After Advisory Board the initiative group edited the draft opinion in accordance with the received comments and suggestions. The final draft of conclusion has been agreed by all experts of the Advisory Board.

The article presents the clinical case of epidermolysis bullosa and atopic dermatitis in child. Such patients require in-patient treatment due to severe progressive course of the disease and the ineffectiveness of therapy.

Levocetirizine is an effective H1-blocker of histamine receptors in complex treatment of various allergic diseases. The article presents the literature data and own observational data on clinical efficacy and safety of levocetirizine in the treatment of allergic diseases such as allergic rhinitis, bronchial asthma, allergic dermatoses.

Background. To study efficacy and safety of Dezrinit (mometasone furoate, metered dose nasal spray, 200 pg/day) in comparison with Nasonex® (mometasone furoate, metered dose nasal spray, 200 pg/day) upon administration for 14 days in adult patients with seasonal allergic rhinitis. Materials and methods. A total of 141 patients were enrolled into the study at 8 study centers in the RF, of which 134 patients were randomized: 67 patients into the experimental group (Dezrinit) and 67 patients into the comparison group (Nasonex®). patients were randomized to receive treatment either with Dezrinit or Nasonex®. Efficacy was assessed based on reflective Total Nasal Symptom Score (rTNSS) and instantaneous Total Nasal Symptom Score (iTNSS); reflective Total Ocular Symptom Score (rTOSS) and instantaneous Total Ocular Symptom Score (iTOSS). Overall proportion of patients who responded to treatment was evaluated according to overall assessment of treatment efficacy both by a patient and by an investigator. AEs were reported for safety assessment. Results. After 14 days of treatment a marked improvement of symptoms was observed in both groups based on all assessed scores. Mean change (SD) in rTNSS from baseline was -11,91 (4,625) scores and -11,64 (4,58) scores in the experimental and comparison groups, respectively (within group differences, p<0,001). Mean difference (SD) in rTNSS from baseline between experimental and comparison groups was -0,2 (0,519) scores [95% confidence interval (CI) -1,231; 0,825]. Analysis of primary efficacy endpoint demonstrated similar results in pp population. Mean change (SD) in iTNSs, rTOSS and iTOSS from baseline was -5,97 (2,569) and -5,93 (2,809) scores; -6,41 (4,801) and -5,09 (4,505) scores; -3,38 (2,4) and -2,54 (2,47) scores in the experimental and comparison groups, respectively (within group differences for all comparisons, p<0,001). Treatment efficacy as assessed by patients and investigators, was evaluated as complete response and significant relief in both treatment groups: 75 and 73,2% investigators in the experimental and comparison groups; 75 and 76,2% patients in the experimental and comparison groups, respectively. No serious adverse events were reported. Conclusion. Available data confirm efficacy comparability and safety of Dezrinit, when compared to Nasonex®, which suggests a possibility of safe replacement of the original drug by the generic product without loss of treatment efficacy.